Stay updated on SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial page.

Latest updates to the SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedIntroduction of a new Informed Consent Form (PDF, 0.31MB) and related study documents, provided by Washington University School of Medicine. These materials are listed under revision 3.5.4, replacing the previous 3.5.3 version.SummaryDifference0.8%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page revision label was updated from v3.5.2 to v3.5.3, indicating a newer version of the study record. This reflects a minor administrative update that does not change the study content or eligibility criteria.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision note updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check65 days agoChange DetectedUpdated the follow-up time frame for several outcomes. The period from 91 days through completion of follow-up (estimated 24 months) was replaced with 91 days through 12 months post-SBRT or 90 days after the last defactinib dose, whichever comes first (estimated 12 months 5 days).SummaryDifference0.3%

- Check73 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check80 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

Stay in the know with updates to SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial page.